Latest ASX Announcements

ASX Announcement – Dimerix appoints Medical Advisory Board

We are very pleased to announce the appointment of a Medical Advisory Board (MAB) to help guide the Company’s DMX-200 clinical program.

The Medical Advisory Board will provide clinical and strategic input into the Company’s lead program, DMX-200 in Chronic Kidney Disease and will provide guidance to the Company as it shapes and progresses its DMX-200 […]

By | 2017-10-18T11:07:50+00:00 October 18th, 2017|Latest ASX Announcements|

Dimerix receives $545k Research and Development Tax Refund

Dimerix (ASX:DXB) is pleased to announce the receipt of a Research and Development (R&D) Tax Incentive refund of $545,771 for the 2016/2017 financial year.

The refund relates to eligible expenditure on the company’s lead program, DMX-200, which has just completed a successful Phase 2a trial, meeting its primary endpoint (safety and tolerability) and showing signals of […]

By | 2017-10-17T11:43:55+00:00 October 17th, 2017|Latest ASX Announcements|

ASX Announcement – WA Broker Meets Biotech presentation

Dimerix CEO Kathy Harrison is pleased to be speaking alongside a great collection of other biotech companies at the Western Australian AusBiotech Broker Meets Biotech event today.

Date: Wednesday 13 September 2017
Time: 1:00pm arrival for a 1:30pm start

Venue: Parmelia Hilton Perth
14 Mill Street
Perth, WA

Details and registration for the event are available

By | 2017-09-13T09:15:19+00:00 September 13th, 2017|Latest ASX Announcements|

Dimerix announces DMX-200 tablet manufacture and human pharmacokinetic study timeline

Dimerix Limited (ASX: DXB), is pleased to announce that manufacturing has been scheduled for later this month to produce the extended release tablet of propagermanium which will be used in the Company’s DMX-200 human pharmacokinetic study and Phase 2b trial in Chronic Kidney Disease.

Read the full release here.

By | 2017-09-05T07:49:25+00:00 September 5th, 2017|Latest ASX Announcements|